Transparency Market Research Report Added "Stem Cell Umbilical Cord Blood Market" to its database.
Albany, NY -- (SBWIRE) -- 05/09/2016 -- Stem Cell Umbilical Cord Blood Market: Overview
Umbilical cord blood (UCB) stem cells have gained much significance in medical science owing to their ability to transform into any type of human cells. UCB refers to the blood that remains in the attached umbilical cord and placenta after childbirth. Stem cells that UCB contains are considered unique in their applicability in treating several life-threatening diseases. UCB stem cells are also used to treat genetic and hematopoietic disorders.
The cord blood collected during childbirth is cryopreserved and stored. UCB stem cells are stored either at private cord banks or at public cord blood banks. This preserved blood is generally used at the time of treatment of chronic ailments or transplantation, if needed, in the later stages of life.
Governments around the world have been proactively financing campaigns to spread public awareness about the potential benefits of UCB stem cells. This has been a crucial factor boosting the global stem cell umbilical cord blood market in the last few years. Furthermore, such steps taken by governments also provides economic and social benefits.
The report covers the various factors influencing the growth exhibited by the stem cell umbilical cord blood market. It features an in-depth analysis of the key market drivers, restraints, and opportunities. Other highlights of the report include a market attractiveness analysis, representation of prominent enterprises in the market in terms of key shares, competitive analysis, SWOT analysis, and Porter's five forces analysis.
Stem Cell Umbilical Cord Blood Market: Key Trends and Opportunities
UCB stem cells have emerged as an effective treatment option for over 80 diseases including immunodeficiency disorders, cancer, and other chronic blood disorders. Many of these diseases have no cure but can be treated effectively using stem cells obtained from the umbilical cord. UCB stem cells travel to the location of the damage, identify the infected cells, and then initiate a healing process. Moreover, the risk of rejection is nonexistent, because they are obtained from the same individual.
With research being underway for developing UCB stem cells to effectively treat diseases such as Alzheimer's, diabetes, heart failure, and brain tumor, the future of the global stem cell umbilical cord blood market seems very impressive. Owing to their inherent health benefits, UCB stem cells are identified as a successful mode of treatment for various life-threatening ailments.
Government authorities are also supporting clinical trials and research into cord blood stem cells, which has been a crucial factor increasing the interest of the healthcare industry and compelling major healthcare players to invest in the commercialization of UCB stem cells therapies. For instance, Cytori Therapeutics Inc., Athersys, and California Stem Cell Inc. are engaged in developing novel stem cell therapies from UCB stem cells. This is a key factor offering impetus to the global market for stem cell umbilical cord blood.
Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10547
Stem Cell Umbilical Cord Blood Market: Competitive Outlook
Competition prevailing in the global stem cell umbilical cord blood market is currently intense, with enterprises focusing mainly on creating brand awareness. This is compelling enterprises operating in the market to formulate innovative strategies. To study the competition prevailing in the market, the report profiles companies such as Nuo Therapeutics, Teva Pharmaceuticals, Cytori Therapeutics, and others.
These companies are studied on the basis of their financial overview, business structure, supply chain network, strategies adopted, and current development status.
Mr. Sudip S
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453